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Etanercept, a recombinant human tumor necrosis factor (TNF) receptor fusion protein, is FDA approved for pso-
riasis and psoriatic arthritis. TNFa increases the synthesis of proinﬂammatory cytokines and leads to the activation
of multiple signaling pathways, including nuclear factor kappa B (NF-jB). The Rel/NF-jB transcription factors play
a central role in numerous cellular processes, including the stress response and keratinocyte proliferation and
differentiation. Utilizing a phosphorylation-specific antibody, we examined the expression of active nuclear NF-jB/
RelA via immunohistochemistry in normal skin, non-lesional psoriatic skin, lesional psoriatic skin, and lesional
skin from patients treated with etanercept. There was no expression of active nuclear NF-jB in the normal ep-
idermis, whereas a basal level of constitutive active phosphorylated NF-jB/RelA was present in uninvolved ep-
idermis from psoriasis patients. There was also significant upregulation of active phosphorylated NF-jB/RelA in
the epidermis from psoriatic plaques. Serial biopsies from psoriasis patients treated with etanercept at 1, 3, and
6 mo demonstrated a significant downregulation of phosphorylated NF-jB/RelA, which correlated with decreases
in epidermal thickness, restoration of normal markers of keratinocyte differentiation, and clinical outcomes. These
data suggest that activation of NF-jB plays a significant role in the pathogenesis of psoriasis and that a potential
mechanism of action for TNF-targeting agents is downregulation of NF-jB transcriptional activity.
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Psoriasis is a chronic papulosquamous disease that affects
1%–3% of the US population (Greaves and Weinstein,
1995; Lebwohl, 2003). It is commonly accepted that the two
major pathological lesions observed in psoriasis are epi-
dermal hyperproliferation with abnormal differentiation, and
an inflammatory infiltration of the epidermis and dermis
(Chaudhari et al, 2001). In the past, therapies for psoriasis
had focused on treating epidermal hyperplasia, which was
hypothesized to occur as a result of the abnormal prolifer-
ation and differentiation of basal keratinocytes (Bayliffe et al,
2004). It later became evident that there was a direct role for
T cells in the pathogenesis of psoriasis (Bos et al, 1983). An
important experimental result, which confirmed the direct
link between T lymphocytes and psoriasis, was demon-
strated by utilizing a fusion protein with specific cellular
toxicity to cells expressing functional interleukin-2 (IL-2) re-
ceptors. Patients treated with deneleukin difitox (Ontak,
Ligand Pharmaceuticals, San Diego, California), which did
not specifically affect keratinocytes, exhibited clinical reso-
lution of psoriasis with histological reversal of epidermal
hyperplasia (Gottlieb et al, 1995). This work set the founda-
tion for additional studies over recent years that have cul-
minated in the current view that the psoriatic process is
driven by an orchestrated interplay between activated T
cells, antigen-presenting cells (APC), and keratinocytes
(Krueger, 2002), which leads to the release of numerous
cytokines and chemokines that signal keratinocytes to
hyperproliferate and undergo abnormal differentiation (Wer-
ner and Smola, 2001; Gottlieb et al, 2003b). Moreover, T cell
activation is attributable to an ongoing stimulus delivered to
T cells by APC and keratinocytes in the skin lesions creating
a self-sustaining positive feedback loop. Given such a com-
plex and multifactorial process it is not surprising that if
these events were to perpetuate, a chronic inflammatory
state would occur.
This immunological basis and theory of the disease has
led to the development of targeted therapies with the
promise of improved efficacy and safety profiles (Asadullah
et al, 2002). Examples of biological agents in use or in con-
tinuing trials include etanercept (soluble anti-TNF (tumor
necrosis factor) receptor) and infliximab (antibody targeted
Abbreviations: APC, antigen-presenting cell; CBP, Creb-binding
protein; CD, cluster of differentiation; CLA, cutaneous lymphocyte
antigen; Cox-2, cyclo-oxygenase 2; EBV, Epstein–Barr virus; HAT,
histone acetyltransferase; HAT, histone acetyltransferase; HDAC,
histone deacetylase; IkBa, I kappa B alpha; ICAM, intercellular
adhesion molecule; IFN, interferon; IKK, IkB kinase; IL, interleukin;
IL-1b, interleukin 1 beta; LFA, lymphocyte function-associated an-
tigen; MMP, matrix metalloprotease; NF-kB, nuclear factor kappa
B; p/CAF, p300/CBP associated factor; TBP, TATA binding protein;
TFIIB, transcription factor IIB; TNFa, tumor necrosis factor a; UVB,
ultraviolet B
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against soluble TNFa), which target TNF activity, as well as
alefacept (lymphocyte function-associated antigen 3 (LFA-
3)/IgG1 fusion protein, which binds to CD-2 receptors on
T cells and blocks the interaction of CD-2/LFA-3), and
efalizumab (anti-CD11a (LFA-1), which blocks the cost-
imulatory signal between LFA-1/ICAM-1) which targets the
APC and T cell interaction.
TNFa controls and regulates the expression of numerous
genes, and in doing so leads to cutaneous responses to
environmental damage and inflammation. Although TNFa
regulates immune and inflammatory responses, it has also
been shown to effect tissue remodeling, cell motility, the cell
cycle, and apoptosis (Gottlieb et al, 2003a; Gugasyan et al,
2004). This tremendous diversity is accomplished by in-
ducing a characteristic set of downstream effectors. One of
these effectors is the transcription factor nuclear factor
kappa B (NF-kB).
The Rel/NF-kB proteins belong to a family of related
transcription factors, which over the last 25 y have been
characterized in most cell types and lineages (Baldwin,
1996). The regulation of gene activation by NF-kB involves
the general transcription machinery as well as coactivators
and chromatin-modifying factors (Schmitz, 1995; Schmitz
and Baeuerle, 1995; Schmitz et al, 1995; Zhong et al, 1998).
Another level of regulatory complexity involves the role that
phosphorylation of Rel family members, such as Rel A,
plays in its interaction with coactivators such as CBP/p300
and its ability to activate target gene transcription (Zhong
et al, 1998).
NF-kB regulates the expression of an exceptionally large
number of genes and has a well-characterized role in im-
mune and inflammatory responses as well as in the pro-
tection against apoptotic cell death (Siebenlist et al, 1994;
Barnes and Karin, 1997; Sonenshein, 1997). Moreover, a
large and diverse set of distinct stimuli activate NF-kB
(Ghosh et al, 1998). NF-kB is also highly activated at sites of
inflammation in a diverse set of human diseases (Tak and
Firestein, 2001). Altogether, these findings underscore the
important role, which NF-kB plays within the immune sys-
tem, and the potential of developing therapeutic agents that
affect NF-kB function as a means to treat inflammatory
disease.
Given the important role that NF-kB plays in regulating
the expression of numerous target genes, and the resulting
consequences for several human diseases, it is not sur-
prising to find that a complex regulatory scheme controls
Rel/NF-kB transcriptional activity. One of the most well-
characterized mechanisms is the control of NF-kB subcel-
lular localization by IkB family proteins (Beg et al, 1992). The
elimination of IkBa allows NF-kB to accumulate in the nu-
cleus and activate target gene expression (Maniatis, 1997).
Interestingly, IkBa is also a transcriptional target of NF-kB
and can downregulate further expression in an autoregula-
tory manner (Maniatis, 1997). A second level of regulation of
NF-kB activity involves phosphorylation and occurs at the
level of activation of the transcriptional activity of RelA
(Wang and Baldwin, 1998). When IkB is degraded, RelA
undergoes phosphorylation that results in transcriptional
activity (Wang and Baldwin, 1998; Zhong et al, 1998). The
activity of NF-kB is also regulated through interactions with
coactivator and corepressor proteins. Recent data showed
that NF-kB-dependent transcriptional activation requires
the coactivators CBP/p300 (Gerritsen et al, 1997). The
phosphorylation of RelA enhances NF-kB transactivation by
promoting the interaction of p65 with CBP (Zhong et al,
1997) and has been shown to be required for NF-kB-de-
pendent gene expression (Sheppard et al, 1999; Wang et al,
1999c). Therefore, NF-kB activity is regulated in a complex
manner and at multiple levels by a large number of proteins.
It is evident from this discussion that TNFa-mediated in-
duction of synthesis of all these factors via NF-kB in lymph-
ocytes, endothelial cells, dendritic cells, and keratinocytes
mediates and increases the cellular infiltrate into the skin
and simultaneously leads to keratinocyte hyperproliferation
in psoriasis (Krueger, 2002). Therefore, it can be postulated
that TNFa produced locally within psoriatic lesions creates a
TNF positive feedback loop that amplifies and sustains the
inflammatory process within plaques (Banno et al, 2004).
Etanercept is a fusion protein of two p75 TNF-receptor
chains and fragments of the Fc region of human IgG. It is
FDA approved for adult and juvenile rheumatoid arthritis,
ankylosing spondylitis, psoriatic arthritis, and psoriasis.
Phase II Trials with etanercept in psoriasis demonstrated a
decrease in PASI (Psoriasis Area and Severity Index), ep-
idermal T cell infiltration, epidermal thickness, as well as
reversal of K-16 keratin expression that indicated a reduc-
tion of inflammation and a return to normal keratinocyte
proliferation and differentiation (Gottlieb et al, 2003b).
Due to the high levels of expression of TNF in psoriatic
patients, the success of anti-TNF treatments, and the role of
NF-kB in TNF signaling, we wanted to explore the link be-
tween active NF-kB and psoriasis. Specifically, we wanted
to determine whether there were differences in the expres-
sion of phosphorylated RelA/p65 between normal and
psoriatic epidermis, and secondarily, if there was upregu-
lation of phospho-NF-kB in lesional psoriatic skin. In addi-
tion, we wanted to determine if the levels of phospho-NF-
kB correlated with abnormalities in lesional skin, such as
a hypertrophic epidermis and abnormal keratinocyte dif-
ferentiation markers. Finally, we wanted to determine if
treatment of psoriatic patients with the anti-TNF agent,
etanercept, would result in downregulation of NF-kB and in
turn if this would correlate with disease resolution and res-
toration of the epidermis to non-lesional appearance. If the
transcriptionally active form of NF-kB were downregulated
in response to etanercept treatment, this would offer one
plausible mechanistic explanation for the drug’s success in
the treatment of psoriasis.
Results
Absence of phosphorylated p65/RelA in normal skin Al-
though multiple studies endeavored to examine the expres-
sion pattern of NF-kB family members in the epidermis and
dermis, none have characterized the expression of the ac-
tive phosphorylated form of RelA/p65 in the epidermis. Be-
cause of the critical role that NF-kB plays in inflammatory
responses, cellular proliferation, the cell cycle, and apop-
tosis and the contradictory reports of its specific function in
keratinocytes, we wanted to study the expression of NF-kB
in both normal and psoriatic skin to establish, not only if
1276 LIZZUL ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
differences existed but if those differences would correlate
with disease status and response to therapy. Toward this
end, we utilized a phospho-specific antibody targeted to
serine 536 of RelA/p65, which is essential for transcriptional
activation by NF-kB. Skin samples were obtained from 4
healthy volunteer controls. Although it has been reported
that a basal level of NF-kB exists in the epidermis (Takao
et al, 2003), we found almost no active nuclear phosphory-
lated RelA in the nucleus of epidermal cells (Fig 1A). Ac-
tivation of NF-kB was confirmed utilizing the phospho-RelA
antibody on samples of normal skin that were irradiated
with UVB, a known inducer of NF-kB activity. This UVB
treatment led to a substantial (po0.02) 25-fold increase in
the level of phosphorylated RelA (Fig 1B and C).
Phosphorylated p65/Rel is present at basal constitutive
levels in keratinocytes from non-lesional psoriatic
skin In light of the overwhelming evidence of the role of
NF-kB family members in immune regulation, apoptosis,
keratinocyte regulation, and psoriasis, we wanted to exam-
ine whether the expression pattern of active nuclear phos-
phorylated NF-kB differed between normal and psoriatic
skin. There is established precedence for abnormal expres-
sion and regulation of proteins and cytokines in disease
processes, including psoriasis (McKenzie and Sabin, 2003;
McKenzie et al, 2003). Therefore, we compared expression
of active phosphorylated RelA/p65 in the normal epidermis
to the non-lesional skin in our psoriasis patients. The skin
samples were obtained from biopsies in ten patients who
were subjects in a study of the efficacy and safety of the
TNF-targeting pharmaceutical etanercept. Interestingly, and
in contrast to the absence of active RelA in the epidermis
from normal patients, those biopsies taken from the unin-
volved skin of psoriatic patients demonstrated substan-
tial basal levels of phospho-RelA/p65 in the epidermis
(po0.02). Specifically, there was an average 12-fold in-
crease of active nuclear phosphorylated RelA/p65 in the
nonlesional psoriatic epidermis compared to normal donor
skin (Fig 2). These data demonstrate a significant difference
in the expression of NF-kB in the epidermis of psoriatic
patients as compared with normal controls.
Phosphorylated p65/Rel is significantly upregulated in
keratinocytes within psoriatic plaques The differential
expression of phosphorylated RelA between normal skin
and non-lesional skin from psoriasis patients prompted ex-
amination of the epidermis from lesional psoriatic plaques
for active nuclear phosphorylated NF-kB expression. As
shown in Fig 3, on average, there was a 5-fold increase
(po0.001) in phospho-RelA in the epidermis of plaques
as compared with uninvolved skin from the same patient. In
additional, there was a substantial increase in epidermal
Figure 1
Absence of active phosphorylated RelA/p65 in the normal epidermis. Punch biopsies from four control subjects were analyzed by
immunohistochemistry for expression of nuclear phosphorylated nuclear factor kappa B (NF-kB)/RelA as described in Materials and methods. A
representative sample shows strong expression of phosphorylated p65 was only detected in UVB-treated samples (compare A to B). The arrows
denote examples of positive cells. No staining was observed with a negative control rabbit IgG antibody. (C) Chart demonstrating the average
number of keratinocytes in epidermis expressing phosphorylated NF-kB/RelA. Denotes a significance of po0.02.
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thickness, as well as expression of abnormal kera-
tinocyte differentiation marker K16 (as has been previously
reported).
Etanercept reduces phosphorylated NF-jB/RelA levels
and reverses abnormal epidermal proliferation and dif-
ferentiation The high levels of TNFa and NF-kB found in
the skin of psoriatic patients coupled with the success of
recent immunologic therapies targeting TNF and immune
receptors in the treatment of psoriasis prompted us to ex-
amine what effect etanercept therapy would have on
phospho-RelA/p65 levels. We also wanted to determine if
treatment with etanercept would lead to histological chang-
es in keratinocyte differentiation and plaque morphology. To
see if TNF’s beneficial effects could be mediated via a de-
crease in NF-kB activation we examined biopsy samples
from etanercept patients at 0, 1, 3, and 6 mo. Consistent
with the fact that NF-kB is a downstream effector of TNF, we
observed that the high levels of nuclear phosphorylated
RelA/p65 shown previously were dramatically reduced
(po0.001) at each successive treatment interval (Fig 4A
and 4B). Interestingly, this decrease in NF-kB was comple-
mented by a significant reduction in epidermal thickness
(po0.01) at each time period (Fig 4A). There was a signif-
icant correlation between these two outcome measures
(Table I). Moreover, examination of keratinocyte differentia-
tion also demonstrated a return of K16 levels to normal in
70%–80% of patients at 3 and 6 mo and this too correlated
with the observed reduction in phosphorylated RelA/p65
(Table I).
Discussion
This is the first report of an in vivo study to demonstrate a
relative absence of nuclear phosphorylated RelA in normal
skin, that non-lesional psoriatic skin contains a basal level
of phosphorylated RelA, and significant overexpression of
phospho-RelA in the epidermis of psoriatic plaques. The
treatment of psoriatic patients with etanercept over a 6-mo
period led to a dramatic downregulation of phospho NF-kB/
RelA in keratinocytes and this correlated with a dramatic
reduction in epidermal hyperplasia/thickness and a return of
normal keratinocyte markers of differentiation. Importantly,
these patients also showed dramatic clinical improvement.
Figure 2
Increased expression of phosphorylated nuclear factor kappa B (NF-jB)/RelA in uninvolved psoriatic skin. The expression of nuclear
phosphorylated RelA was examined via immunohistochemistry in four control subjects and ten psoriasis patients as explained in the Materials and
methods utilizing a specific anti-phospho NF-kB antibody. (A) Chart depicting the average number of keratinocytes in the epidermis expressing
nuclear phosphorylated RelA. Denotes significance of po0.02. (B) Immunohistochemical analysis demonstrated the dramatic difference in ex-
pression levels of nuclear phosphorylated p65 between normal epidermis and the non-involved epidermis from psoriasis patients. Slide is a
representative sample from the study population and the arrows denote examples of positive nuclear staining cells.
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In the absence of stressful stimuli, NF-kB is present in
the cytoplasm in a resting state within normal keratinocytes
(Takao et al, 2003). Under normal conditions, NF-kB has
also been noted to play an important role in keratinocyte
regulation and proliferation (Takao et al, 2003; Bernard et al,
2004). But the function of NF-kB in keratinocytes has been
proposed to be quite paradoxical to its effect in other cell
types, such as T or B cells (Dajee et al, 2003). Skin defects
are present in a number of mouse models in which Rel/NF-
kB function is perturbed (Gerondakis and Strasser, 2003).
For instance, the epidermis restricted expression of a
dominant negative form of IkB produced by mice with
profoundly hyperplastic epithelia whereas mice that over-
expressed RelA/p65 showed epidermal hypoplasia and
growth inhibition (Takeda et al, 1999; Seitz et al, 2000a, b).
This is in contrast to studies on mice null for IkBa which
demonstrate marked alterations in epidermal morphology,
including hyperplastic epidermal keratinocytes and dermal
infiltration of lymphocytes (Wilson et al, 1990; Chen et al,
2000a, 2000b; Lee et al, 2000; Bell et al, 2003).
The reason for this diversity in outcome of NF-kB acti-
vation may be a reflection of the cell type and different-
atiation state of the cell (Ozes et al, 1999; Romashkova and
Makarov, 1999; Ernfors, 2000). An interesting model pro-
posed by Kaufman and Fuchs (2000) tries to take into
account the peculiar findings of NF-kB activity in the
epidermis. They suggest that a balancing act is played be-
tween cell-cycle withdrawal, cell survival and differentiation.
In addition to an apparent cell-cycle arrest effect, NF-kB in
the epidermis also protects against apoptosis by enhancing
the expression of anti-apoptotic factors (Wrone-Smith et al,
1997; Seitz et al, 2000b). It is through a marriage of cell-
cycle withdrawal and protection against apoptosis that
NF-kB is able to coordinate homeostasis within the normal
epidermis.
The data and models discussed above are all in refer-
ence to normal skin, normal epidermis, and normal kera-
tinocytes. Psoriasis is clearly an abnormal state, and one
would anticipate changes in the epidermis and keratin-
ocytes. Perhaps, this is why we observed, in contrast to our
control subjects, a basal level of nuclear phosphorylated
RelA/p65 in the non-lesional skin of our psoriatic patients
and in turn this may be one factor, in the backdrop of an
altered cellular milieu, which predisposes to psoriatic
plaque formation. For example, when normal keratinocytes
are co-cultured with psoriatic T cells (Bata-Csorgo et al,
1995) they do not undergo increased growth or hyperpro-
liferation. But keratinocytes established from non-lesional
psoriatic skin are markedly abnormal even before they
are cocultured with lymphocytes (Jackson et al, 1999). In
culture these abnormal keratinocytes release abnormal
amounts of interferon gamma (IFNg), and have subnormal
transcription factor activation in response to cytokine stim-
ulation (Werner and Smola, 2001). Although IFNg promotes
Figure 3
Upregulation of active phosphorylated nuclear factor kappa B (NF-kB) in lesional plaques. The expression of nuclear phosphorylated p65 was
examined by immunohistochemistry in uninvolved and lesional epidermis from ten psoriasis patients. (A) Chart depicting the average number of
phosphorylated NF-kB positive keratinocytes in the epidermis. Denotes significance of po0.001. (B) Representative slide showing enhanced
expression of phosphorylated NF-kB detected in lesional plaques as compared to uninvolved skin. Arrows highlight examples of positive nuclear
staining cells.
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growth arrest of normal keratinocytes (Nickoloff et al, 1984;
Saunders and Jetten, 1994), it induces proliferation of
psoriatic keratinocytes (Baker et al, 1988, 1993). These
findings have led to the hypothesis that the existence of
abnormalities in the signaling pathways of psoriatic kera-
tinocytes predisposes them to display an overactive wound
healing response when exposed to stimulation from inflam-
matory mediators (McKenzie and Sabin, 2003). A recent
study published by Watanabe et al (2004) identified a mu-
tation in Crohn’s disease patients that predisposes them to
the development of the disease. Interestingly, a mutation in
the gene encoding nucleotide-binding oligomerization do-
main 2 (NOD2) appeared to be the culprit. They reported
that the function of NOD2 was to limit the proinflammatory
effects mediated by Toll-like receptor 2 (TLR2) stimulation.
The mutated form of NOD2 found in Crohn’s patients was
unable to inhibit TLR2 signaling, and this apparently skewed
the system towards inflammation. Interestingly, this is an
NF-kB-dependent phenomenon because NF-kB is down-
stream of TLR-2 and its activation leads to production of
Figure 4
Etanercept downregulates expression of phosphorylated nuclear factor kappa B (NF-jB). Punch biopsies from ten psoriasis patients were
examined via immunohistochemistry utilizing an anti-phospho-NF-kB specific antibody as described in Materials and methods. (A) Charts depicting
the average number of keratinocytes expressing phosphorylated RelA and the average epidermal thickness from baseline plaques or at subsequent
etanercept treatment points. Denotes significance of po0.01. (B) Immunohistochemical analysis of a representative sample demonstrating the
reduction of phosphorylated RelA after treatment with etanercept at 1, 3, and 6 mo. Arrows highlight representative positively nuclear staining cells.
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IL-12. Expression of both IL-12 and IL-2 has also been
found to be upregulated in psoriasis (Lee et al, 1988;
Yawalkar et al, 1998).
The increased epidermal thickness present in psoriatic
plaques is the net sum of both rates of proliferation and cell
death. Moreover, aside from high levels of TNFa and NF-kB,
many other cytokines, such as IFNg, and their downstream
targets are upregulated in psoriasis (Bowcock et al, 2001). It
would be naı¨ve to suggest that NF-kB is the sole suspect in
this process, but NF-kB activation is also clearly associated
with resistance to apoptosis (Beg and Baltimore, 1996;
Wrone-Smith et al, 1997; Foo and Nolan, 1999; Wang et al,
1999a, b). Thus, one would predict that blocking NF-kB
activation would make keratinocytes more susceptible to
apoptosis, with fewer rather than more viable cells in the
epidermis. Unfortunately, under normal conditions, the op-
posite is observed with the blockade of NF-kB. How could
such a paradox exist? First, in psoriasis it is clear that the
keratinocytes are not normal; therefore, what is observed
under normal conditions may not apply in this chronic in-
flammatory condition. Second, it would seem reasonable to
consider the context in which we are looking at NF-kB ac-
tivity and to consider the role of other molecular regulators
of apoptosis, the cell cycle and proliferation in the skin. For
example, another major cellular pathway regulated by NF-
kB is the cell cycle (Chaturvedi et al, 1999). It has been
shown that NF-kB activating stimuli such as IFNg and tissue
plasminogen activator (TPA) induce growth arrest in normal
keratinocytes in vitro (Qin et al, 1999). Therefore, the ob-
servation that constitutive activation of NF-kB in transgenic
mice models produced epidermal thinning may in fact rep-
resent a dominance of the cell cycle inhibitory effect over
the anti-apoptotic effect. Thus, although the cells were not
undergoing cell death, they were not proliferating either. So
if we extrapolate to normal skin, it may be that the anti-
proliferative effects of NF-kB are superior to its anti-apopto-
tic effect in the absence of inflammation or apoptotic stimuli.
In support of this view, transgenic mice expressing anti-apo-
ptotic genes Bcl-x or Bcl-2 have no significant increase in
epidermal thickness in the absence of cell-cycle changes. In
fact, it is only when the homeostasis of the skin is altered by
various proinflammatory or tumorigenic stimuli that a dis-
tinctive phenotype becomes apparent (Valle Blazquez et al,
1997; Rodriguez-Villanueva et al, 1998). Such a scenario ex-
ists in psoriasis, therefore the disruption of balance between
cell-cycle inhibitory and proliferative effects would tip the
scale towards epidermal proliferation in the context of a self-
sustaining cytokine-mediated feedback loop.
In agreement with the high levels of TNFa and phos-
phorylated NF-kB found in psoriatic patients, and the cru-
cial link between TNF-mediated signaling and NF-kB, we
observed a substantial and significant reduction in the lev-
els of phospho-NF-kB after treatment with etanercept. This
suggests that NF-kB may not only play an important role in
the pathogenesis of psoriasis, but that it may be a reason-
able therapeutic target. Recent work by Zollner et al sup-
ports this hypothesis. They demonstrated that the inhibition
of superantigen-mediated T cell activation by the selective
proteasome inhibitor PS-519 led to significant resolution of
psoriasis in a severe combined immunodeficiency (SCID-
hu) model (Zollner et al, 2002). PS-519 is known to affect the
inhibitory regulator of NF-kB and IkB, and the work dem-
onstrated a concentration-dependent suppression of NF-
kB DNA binding.
In light of the results from these experiments and the
current literature, we propose a significant role for NF-kB in
the pathogenesis of psoriasis. Although there is ample ev-
idence in the literature to substantiate our utilization of
nuclear-phosphorylated NF-kB as a proxy for NF-kB acti-
vation, relying exclusively on immunostaining to detect
nuclear phospho-RelA does not necessarily indicate a func-
tional state of NF-kB activation. Therefore, although confi-
dent in our results, we recognize the limitation of our in vivo
studies, and have initiated follow-up experiments to reaffirm
our results. Due to limited patient samples, we are utilizing
the remainder of the 6mm biopsy specimens from our study
population to perform RT-PCR-mediated gene expression
studies that will reaffirm the etanercept-mediated repres-
sion of NF-kB activity.
NF-kB’s role in psoriasis is multifactorial, with influence
on T cells, dendritic cells and keratinocytes. In lymphocytes,
downregulation of TNFa leads to downregulation of NF-kB,
which not only abrogates additional TNFa production but
also eliminates the production of necessary inflammatory
cytokines and cell adhesion markers. The role of NF-kB in
the keratinocyte is more complicated and controversial
(Kaufman and Fuchs, 2000). We believe that in the setting of
a chronic inflammatory state such as psoriasis, there is an
imbalance between the anti-apoptotic role and the cell-
cycle inhibitory role of NF-kB whereby the scale is tipped
toward protection against cell death in the context of
a constitutive cytokine-rich inflammatory milieu. This allows
for the increased epidermal thickness and hyperproliferation
Table I. Correlation between reduction in phosphorylated
NF-jB, decrease in epidermal thickness and improvement of
keratinocyte K-16 expression
(A)
Epidermal thickness Normal K-16
Phospho-NF-kB 0.61683 0.55207
p-value o0.001 o0.001
(B)
Normal phospho-NF-jB Normal K-16
Baseline plaque 0/10 1/10
1 mo etanercept 0/10 3/10
3 mo etanercept 4/10 7/10
6 mo etanercept 2/10 8/10
(A) Correlations using pooled data from plaques at baseline, 1, 3, and 6
mo treatment with etanercept as discussed in Materials and Methods.
Pearson correlation coefficients with levels of significance are presented
in table for concomitant reduction of phosphorylated NF-kB and epider-
mal thickness, as well as for restoration of K16 to non-lesional status. (B)
Depicts the return of normal keratinocyte differentiation and proliferation,
as defined as the absence of K16, and the reduction of phosphorylated
NF-kB levels in lesional plaques to the level present in uninvolved skin
from the same patient.
NF-kB, nuclear factor kappa B.
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seen in plaques. Alternatively, perhaps the proposed func-
tion of NF-kB in normal keratinocytes is altered in the ab-
normal keratinocytes present in psoriatic patients and
therefore proliferation and increased thickness is observed
as opposed to cell-cycle arrest. Further work will be needed
to expand on these ideas and confirm the potential benefit
of NF-kB targeted therapies in the treatment of psoriasis as
well as other inflammatory and autoimmune disorders.
Materials and Methods
Patient studies The study was conducted according to the Dec-
laration of Helsinki Principles, and participants gave their written
informed consent. Adult patients with moderate to severe psoriasis
were treated with etanercept monotherapy (25 mg subcutaneously
twice weekly) for 24 wk under a protocol approved by the UMDNJ-
Robert Wood Johnson Medical School Institutional Review Board.
Systemic and photo-therapies were excluded for 1 mo prior to
dosing; topical medications were excluded for 2 wk prior to dosing.
Eucerin cream (Beiersdorf, Wilton, Connecticut) was the standard
moisturizer used throughout the study. Patients were told not to
apply moisturizer prior to study evaluations. Clinical efficacy was
assessed using PASI. Skin biopsies were obtained at baseline, 1, 3,
and 6 mo. Skin biopsies were snap frozen in optimal cutting
temperature compound (OCT, Tissue Tek, Sakura, Torrance,
California) and saved at 701C. Laboratory-based evaluations
were blinded to the clinical results until all data were collected.
UVB exposure of human subjects Under a protocol approved by
the UMDNJ-Robert Wood Johnson Medical School Institutional
Review Board, four healthy volunteers between the ages of 18–60
were recruited and their minimum erythema dose (MED) was de-
termined. MED of a subject is the minimum dose of UVB light that
induces mild redness (sunburn) on the skin 24 h after the light
exposure. The patients were irradiated with 2 MED of UVB on
either the left or right hip and 6 mm punch biopsy was taken im-
mediately after UVB exposure. Subsequently, two more punch bi-
opsies were taken from each patient at 24 and 48 h after the UVB
light exposure. The biopsies were frozen immediately in OCT and
saved at 701C.
Histology and immunohistochemistry Skin punch biopsy spec-
imens (6 mm) were obtained from target plaques at weeks 0, 4, 12,
and 24. A non-lesional skin biopsy was also obtained at week 0.
Biopsy specimens for UVB-treated skin were obtained on Day 1
immediately after UVB irradiation and at 72 h post-treatment. Serial
cryostat-cut sections were stored at 701C before use. Immuno-
peroxidase studies of the number of epidermal nuclear-staining
phosphorylated NF-kB positive cells and keratinocyte expression
of k16 keratin were performed (Vectastain ABC kit, Vector Labo-
ratories, Burlingame, California) as previously described (Gottlieb
et al, 2003a). Briefly, slides were thawed to room temperature,
fixed in BFA for 15 min, and then endogenous peroxidase activity
was quenched with 0.3% H2O2. After washing in PBS the sections
were blocked for 30 min with goat serum in PBS. The primary
antibody in PBS containing goat serum was applied for 30 min at
room temperature. After rinsing in PBS, sections were incubated
with biotinylated secondary antibody in PBS containing goat se-
rum, washed in PBS, and incubated with Vectastain Elite ABC
Peroxidase reagent (Vector Laboratories). Finally, after rinsing in
PBS, the reaction product was visualized using diaminobenzidine.
Primary antibodies used were anti-phospho RelA/p65 (Cell Signa-
ling Technologies, Beverly, Massachusetts) 1:50, and anti K-16
(1:400). As negative controls, all experiments were performed in
the presence of equal concentrations of normal rabbit IgG isotype
control.
Three blinded investigators, including board certified dermatol-
ogists, examined immunostained sections with an image analyzer
attached to a light microscope (Image pro-plus 3.1, Mediscy-
bernectic, Silver Spring, Maryland). The average number of pos-
itively nuclear stained epidermal nuclear phospho-NF-kB cells in
five  200 fields was determined. Epidermal thickness was quan-
titated by averaging the epidermal thickness in three  100 fields
in H&E-stained sections. For keratinocyte expression of K16,
semiquantitative scores of 0 to 4þ were assigned for each section
read. Normal expression was defined as 0. Abnormal expression
was defined as 1þ , 2þ , 3þ , or 4þ . There was less than 5%
discordance between observers in all instances.
Statistical methods Statistical analysis was performed using the
paired or unpaired t test unless otherwise specified. Correlation
between variables was analyzed by the Pearson’s correlation co-
efficient. Two-tailed po0.05 was considered to indicate statistical
significance.
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